ClinicalTrials.gg
Sign In

Sarcoma, Kaposi clinical trials

The registry lists 161 studies for Sarcoma, Kaposi across more than 10 countries. 24 are recruiting or about to start. 108 of them are mainly about Sarcoma, Kaposi (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-05. Counting its narrower condition AIDS-related Kaposi sarcoma too: 174 studies, 25 open.

Get an email when these change. Save the Sarcoma, Kaposi studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
105
Recruiting
21
Terminated
13
Active, not recruiting
9
Status unknown
6
Withdrawn
4

Phase

Phase 2
68
Phase 1
51
Phase 3
9
Early Phase 1
2
Phase 4
2

Where

United States
115
Uganda
8
Italy
7
Israel
5
France
5
South Africa
4

Who runs them

National Cancer Institute (NCI) (36) · National Institute of Allergy and Infectious Diseases (NIAID) (17) · AIDS Malignancy Consortium (15) · Alpha Tau Medical LTD. (5) · Sequus Pharmaceuticals (4) · University of California, San Francisco (4) · Washington University School of Medicine (4) · Memorial Sloan Kettering Cancer Center (4)

What is being tested here

Drugs under test in Sarcoma, Kaposi studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Nivolumab206
Propranolol202
Doxorubicin159
Liposomal doxorubicin113
Pomalidomide103
Paclitaxel113
Abemaciclib101
Immunocytokine NHS-IL12101
Daratumumab101
Interleukin 7101

Drug classes tested here Immune checkpoint inhibitors 2 open · Antimitotic agents 1 open · Angiogenesis inhibitors 10 · Tyrosine kinase inhibitors (TKIs) 9 · Reverse transcriptase inhibitors 5

Coming up

1phase 3 study under way
6studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 6

Who these studies take

Of the 21 Sarcoma, Kaposi studies recruiting now, 11 (52%) set no upper age limit and 1 (5%) stop at 75 or younger. 2 (10%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (5%) take healthy volunteers.

Recruiting studies that take each age, of 21
AgeWomenMen
101 (5%)1 (5%)
1820 (95%)20 (95%)
3021 (100%)21 (100%)
4020 (95%)20 (95%)
5020 (95%)20 (95%)
6520 (95%)20 (95%)
7520 (95%)20 (95%)
8520 (95%)20 (95%)

Across all 161 studies, recruiting or not: 6% stop at 75 or younger and 3% at 65; 13% take children; 0% are for women only and 2% for men only; 2% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Sarcoma, Kaposi studies take

Of 22 phase 2 interventional studies under Sarcoma, Kaposi, half reached primary completion within 72 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 272 mo46–84 · 22 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 161. Browse all 161 → or search them.